Document Detail


Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.
MedLine Citation:
PMID:  12167396     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To estimate the cost-effectiveness of adding ramipril to conventional treatment in patients with heart failure after myocardial infarction from the perspective of the Spanish National Health System.
METHODS AND RESULTS: A retrospective analysis of the AIRE study was made, using previously published data from the clinical trial combined with local Spanish resource and cost data. A typical rehospitalisation for a heart failure episode would last an average of 11.6 days with an average cost of 350.80 per day. The incremental cost of ramipril per life-year gained in the baseline case was 1550.10 after 3.8 years of follow-up. Sensitivity analysis showed that the basic conclusions were robust in spite of extreme variations in the values of the key parameters of the model.
CONCLUSION: The use of ramipril in addition to conventional treatment in heart failure patients after myocardial infarction is cost-effective both according to currently accepted international standards of what constitutes a cost-effective intervention and also indirectly by comparing the results with similar pharmaceutical products financed under the Spanish National Health System.
Authors:
Warren Mark Hart; Carlos Rubio-Terres; Francisco Pajuelo; Jose R González Juanatey
Related Documents :
23492596 - Left atrial appendage closure devices. their role in 2013.
18650976 - Beneficial effects of sauna bathing for heart failure patients.
24485606 - What can three-dimensional speckle-tracking echocardiography contribute to evaluate glo...
1971596 - Xamoterol monotherapy in heart failure. the european 'corwin' group.
8024486 - Severe electrolyte disturbances in lethal subclavian catheter dialysis.
12685146 - Suppression of electrical storm by biventricular pacing in a patient with idiopathic di...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of heart failure     Volume:  4     ISSN:  1388-9842     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-08-08     Completed Date:  2002-10-29     Revised Date:  2011-06-08    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  553-8     Citation Subset:  IM    
Affiliation:
EcoStat Consulting Group, San Sebastián, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  economics*,  therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Drug Therapy, Combination
Heart Failure / drug therapy,  economics*
Humans
Length of Stay / economics
Myocardial Infarction / drug therapy,  economics*
Patient Readmission / economics
Ramipril / adverse effects,  economics*,  therapeutic use
Retrospective Studies
Spain
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 87333-19-5/Ramipril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical depression is common and significantly associated with reduced survival in patients with no...
Next Document:  Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH.